




Cite this: *Nanoscale*, 2024, **16**, 21582

Star-polymer unimolecular micelle nanoparticles to deliver a payload across the blood–brain barrier†

Mehak Malhotra,^a Meenakshi Pardasani,^b Shahidkhan Pathan,^a Priyadharshini Srikanth,^b Karishma Shaw,^b Nixon M. Abraham ^{*b} and Manickam Jayakannan ^{*a}

Nanocarrier-mediated therapeutic delivery to brain tissue is impeded by tightly controlled transportation across the blood–brain barrier (BBB). Herein, we report a well-defined core–shell star-shaped unimolecular micelle (star-UMM; a single polymer entity) as an efficient BBB-breaching nanoparticle for brain-specific administration of the fluorescent anticancer drug doxorubicin and *in vivo* mapping of brain tissues by the near-infrared biomarker IR780 in mice. The star-UMM was engineered by precisely programming the polymer topology having hydrophobic and hydrophilic polycaprolactone blocks and in-built with lysosomal enzyme-biodegradation stimuli to deliver the payloads at intracellular compartments. *In vivo* imaging in mice revealed prolonged circulation of star-UMM in blood for >72 h, and whole-organ image-quantification substantiated its efficient ability to breach the BBB. Star UMM exhibited excellent stability in blood circulation and reduced cardiotoxicity, was non-hemolytic, had substantial uptake in the cortical neurons of the mouse brain, had lysosomal enzymatic-biodegradation, and exhibited negligible immunogenicity or necrosis. This newly designed star-UMM could have long-term applications in brain-specific drug delivery.

Received 26th June 2024,
Accepted 13th October 2024

DOI: 10.1039/d4nr02636e

rsc.li/nanoscale

Introduction


Drug delivery across the tightly regulated vasculature of the blood–brain barrier (BBB) in treating tumors and neurodegenerative diseases has been a major bottleneck.^{1–3} The BBB maintains the homeostatic balance by regulating the transport of small-molecule nutrients and ions through the vasculature into the brain; thus, restricting the transportation of larger size and extraneous species across this biological barrier.⁴ Nano-prodrug development has clearly identified that carriers <50 nm in size can penetrate the BBB and enable drug accumulation in the brain.^{5–9} Polypeptide nanoparticles (NPs), tumor-derived extracellular vesicles, synthetic protein NPs, nano-antioxidants, liposomes, dendrimers, worm-like

micelles, and T cell-mediated polymer NPs are some of the important examples reported for BBB research.^{10–23} Intranasal²⁴ and gut-to-brain oral drug-delivery models²⁵ have also been developed to overcome BBB challenges encountered by intravenous delivery pathways. Near infrared (NIR)-assisted fluorescent NPs have been utilized for image-guided therapy for Parkinson's disease²⁶ and glioblastoma.²⁷ Uncontrollable glomerular renal filtration of smaller (<15 nm) nanocarriers, and splenic and hepatic filtration of bigger NPs (>200 nm) in the body limits the drug concentration of the NP formulation upon intravenous administration which, in turn, reduces the bioavailability of NPs for BBB crossing.^{28,29} Thus, the next generation of BBB-crossing nanocarriers is mandatorily designed to be substantially stable to evade disassembly in body fluids *in vivo*, tiny-size sub-nanometer objects (<50 nm) for penetrating tightly regulated *t*-junctions, high drug-loading content, reduced cardiotoxicity and, most importantly, biodegradable for safe use in BBB research.^{30–34} Among the many synthetic NPs, branched macromolecular architectures such as “star block” copolymers exhibit resistance against renal filtration and retain the drug NP formulation in the blood for prolonged periods.²⁹ Star-block copolymers provide excellent structural control to build well-defined core–shell NPs.^{35–40} Persistent to their three-dimensional globular core–shell

^aDepartment of Chemistry, Indian Institute of Science Education and Research (IISER Pune), Dr Homi Bhabha Road, Pune 411008, Maharashtra, India.

E-mail: jayakannan@iiserpune.ac.in

^bLaboratory of Neural Circuits and Behaviour (LNCB), Department of Biology, Indian Institute of Science Education and Research (IISER Pune), Dr Homi Bhabha Road, Pune 411008, Maharashtra, India. E-mail: nabraham@iiserpune.ac.in

†Electronic supplementary information (ESI) available: Synthesis, structural characterization and additional biological data are provided. See DOI: <https://doi.org/10.1039/d4nr02636e>


geometry, star polymers often exist as unimolecular micelles^{41,42} which is highly desirable for *in vivo* drug administration to maintain the drug NP against the concentration gradient in the bloodstream. Herein, for the first time, these unique features of the star-polymer unimolecular micelles (star-UMM) were explored for BBB research based on biodegradable polymer “nanovectors”, and the proof-of-concept was demonstrated *in vivo* for the clinically important anti-

cancer drug doxorubicin (DOX) and brain tissue-penetrable NIR biomarker IR-780. This new strategy is shown in Fig. 1.

“Tweaking” the topology of the macromolecular architectures was found to be a crucial factor in designing the star-UMM. For this purpose, hydrophobic polycaprolactone (PCL) and carboxylic-substituted hydrophilic PCL segments were chosen based on our efforts.^{43–55} Systematically, several structures, such as linear di-blocks, star di-blocks, and star random





Fig. 1 New strategy for breaching the blood–brain barrier. (a) Design and development of biodegradable star block copolymer unimolecular micelles (UMM) for brain-specific delivery. (b) Different chemical structures of star and linear block copolymer architectures reported in the present investigation.



copolymers, were “tailor-made” by ring-opening polymerization (ROP) to get the correct polymer geometry with high encapsulation capabilities. All these structures (including their linear polymer counterparts) were traced to obtain the “ideal” star-UMM platform with the ability to breach the BBB. Furthermore, the periphery of the star-UMM was decorated with an anionic charge. This is crucial for efficient penetration into brain tissue,^{56,57} long circulation against renal filtration in the blood stream⁵⁸ and, most importantly, to elicit appropriate amphiphilicity for loading and delivering cargoes. The *in vivo* biodistribution data established the supremacy of the star-UMM platform for crossing the BBB with reduced side-effect of cardiotoxicity. Furthermore, microtubule-assisted protein 2 (MAP2), neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) immunostaining were employed to mark the different cell types across brain tissue to ascertain the neural uptake of star-UMM. Our approach opens up new research opportunities based on biodegradable star polymer macromolecules as potential futuristic single molecular-like star-UMM NPs to breach the BBB and be useful for long-term brain-specific drug delivery.


Results and discussion

Star-block copolymers were constituted with a PCL core and γ -^tButyl ester-substituted PCL segments at the periphery (as shown in Fig. 2a) employing an in-house built melt reactor (Fig. S1a†) to perform solvent-free ring-opening polymerization (ROP). Three star-polymers were synthesized in a sequential ROP process in which initial polymerization of ϵ -caprolactone (CL) yielded a six-arm PCL macroinitiator (MI) having statistically 5, 10 and 20 units per arm. These PCL MI were subsequently employed for the ROP of γ -^tButyl ester-substituted caprolactone monomer⁴⁸ (*t*-BECL) (Fig. S1b†), (Fig. 2a and Fig. S1c†) to yield three star-di-block polymers having 35/35, 60/60 and 120/120 units. For instance, the 60/60 di-block had 10 PCL and 10 *t*-BECL units per arm. The star block copolymers (SB) were referred to as “SB-35”, “SB-60”, and “SB-100” where the number represents the total content of carboxylic ester-substituted PCL segments at the periphery. To determine the structure and degree of polymerization (number of units), the peak intensities in ¹H-NMR were analyzed in detail (Fig. S2 and S3a†). For feed $[M]/[PCL\ MI] = 60$, the actual incorporation was determined to be 64 ± 3 repeating units, confirming the statistical distribution of 10 units per arm in the second block (ESI Fig. S2a†). Deprotection of *t*-butyl ester in these star block copolymers yielded their carboxylic acid-substituted PCL block copolymers (¹H-NMR) (Fig. S2 and S3a†). Size-exclusion chromatography (SEC) was employed to determine the M_n , M_w , and polydispersity index (PDI) and the values are summarized in the table in Fig. 2b (SEC plots) (Fig. S3b†). Star-block copolymers were produced in very high molecular weights of 40 kDa to 60 kDa, which are sustainably high enough to fold or self-assemble into a single polymer entity. The thermal properties of these new star polymers are described in Fig. S3c.†

Hydrophilic carboxylic PCL units in the periphery and hydrophobic PCL units in the core provided perfect molecular geometry for the star polymers to acquire the required amphiphilicity. Star block copolymers were self-assembled by a dialysis method (details in the Experimental section). Dynamic light scattering (DLS) revealed the hydrodynamic diameter (D_h) of the star-block copolymer SB-60 to be $D_h = 25 \pm 7$ nm (Fig. 2c). In Fig. 2c, FESEM and AFM images revealed the formation of spherical NPs with average sizes of 23 ± 3 nm and 22 ± 5 nm, respectively. HR-TEM images were in coherence, and the histogram generated (not shown) from ~50 particles gave an average value of 24 ± 4 nm. From these data, the hydrodynamic radius (R_h) of the SB-60 NP was estimated to be 12 ± 3 nm. Small-angle X-ray scattering (SAXS) was employed to determine the radius of gyration (R_g) of SB-60 and, based on the Guinier approximation, the R_g was estimated to be 7.1 ± 2.3 nm (Fig. S4a†). The ratio of R_g/R_h was estimated to be 0.77 with respect to the existence of unimolecular micellar formulations.⁵⁹ A pyrene-encapsulation study showed no change in the ratio of I_1/I_3 at different polymer concentrations, and depicted the unimolecular micelle self-assembly by the star-block copolymer SB-60 and SB-100 (Fig. S4b†). SB-35 was not readily dispersible in water and produced a turbid solution, rendering it unusable. The molecular weights of the polymers increased with an increase in the number of PCL and carboxylic PCL units in SB-35, SB-60 and SB-100. Interestingly, the increase in molecular weights in star block copolymers varied substantially in their aqueous self-assembly. For instance, the shorter-arm star polymer SB-35 self-assembled into aggregated micelles and produced larger size 150 nm NPs, whereas the higher star analogues SB-60 and SB-100 exhibited the formation of unimolecular micelles. The formation of unimolecular micelle seemed to be driven by high molecular weights and the star-polymer design. This was confirmed by comparing the self-assembly of the linear diblock copolymer LB-60, which had an identical mass as that of star SB-60; however, it differed largely in its aqueous self-assembly into aggregated micelles rather than unimolecular micelles. The above analysis denoted the existence of core-shell <30 nm-sized star-UMMs by both SB-60 and SB-100. The pH-dependent zeta potential and size analysis confirmed negatively charged stable NPs across a pH range from 4 to 11 (Fig. S5†).

The encapsulation capabilities of star-UMM NPs were studied for doxorubicin (DOX) and the NIR dye IR780 by the dialysis method (Experimental section). The DLC for SB-60, SB-100, SB-35 was found to be 14.2%, 13.1% and <1% for DOX, respectively (Fig. 3a). This suggested that SB-60 exhibited the most optimized core-shell structure to attain the highest DLC for star-UMM. SB-35 did not have sufficient compartmentalization for DOX loading. The core-shell geometry probably attained maximum packing at SB-60; thus, no significant DLC increase was observed in SB-100. Encapsulation of NIR dye IR780 in SB-60 showed a very good DLC of 5%, which is excellent for deep-tissue bioimaging analysis. The sizes of nascent and DOX-loaded star block copolymer formulations are tabulated in Fig. 2b (DLS plots in Fig. S4c†). All the nano-formu-





(b) Molecular weights and Properties of Star Polymer NP

Star PCL Macroinitiator	Star Block Copolymer	M_n ($^1\text{H NMR}$) (g/mol)	M_n (SEC) (g/mol)	M_w (SEC) (g/mol)	\bar{D}	D_h (nm)	ξ (mV)	PDI	Sample	D_h (nm)	ξ (mV)	PDI
Nascent Star Nanoparticles									DOX Loaded Star Nanoparticles			
S-35	SB-35	13200	21300	36300	1.7	156 ± 2	-16.1 ± 1.5	0.4	SB-35+DOX	135 ± 7	-26.5 ± 2.0	0.1
S-60	SB-60	25200	30200	42000	1.4	25 ± 7	-21.1 ± 1.6	0.4	SB-60+DOX	23 ± 2	-17.9 ± 1.7	0.4
S-110	SB-100	38600	44800	60200	1.3	38 ± 6	-22.8 ± 0.8	0.3	SB-100+DOX	37 ± 2	-21.7 ± 1.6	0.3

(c) Characterization of SB-60 Unimolecular Micelles




Fig. 2 Synthesis and characterization of star polymer nanovector. (a) Synthetic scheme of star block copolymers. The subunits of PCL and carboxylic PCL segments were varied by controlling the monomer/initiator ratio in the polymerization reaction feed. (b) Table containing the molecular weights ($^1\text{H NMR}$, SEC) and polydispersity (SEC) of polymers; hydrodynamic diameter (DLS), zeta potential, polydispersity (DLS) of polymers in a self-assembled state in water (concentration = 0.1 mg mL^{-1}) and their doxorubicin-encapsulated counterparts. Zeta potential for SB-35 and its DOX-loaded sample were measured in distilled water. Zeta-potential measurements for SB-60 and SB-100 and their DOX-loaded sample were measured in Britton–Robinson buffer (10 mM) at physiological pH 7.4. (c) DLS, FESEM, HR-TEM and AFM images were recorded at a concentration of 0.05 mg mL^{-1} in water.

lations showed monomodal size distribution with narrow PDI values. The IR780-loaded star block copolymer SB-60 analogue had a size in the range of $120 \pm 10 \text{ nm}$. The zeta potential for SB60 and SB100 and their DOX-loaded samples were recorded in Britton–Robinson buffer (10 mM), physiological pH 7.4, and the values are reported in the table in Fig. 2b. The zeta potential of SB-35 could not be measured in Britton–Robinson buffer (10 mM) due to uncontrolled precipitation and, therefore, the values were reported in water. The zeta potential of

SB-60 and SB-100 polymers was found to be -21.1 and -22.8 mV , respectively. As anticipated, SB-100 exhibited a slightly higher zeta potential due to the increase in the number of carboxylic acids. Similar trends were observed for their DOX-loaded samples as well. The zeta potential did not show a drastic change when increasing the number of carboxylic units from 60 in SB-60 to 100 in SB-100. This could be attributed to the fact that the charges were saturated on the periphery of the polymer nano-assemblies at 60 carboxylic




Fig. 3 *In vitro* cellular studies and live cell imaging. (a) Drug-loading content (DLC) for doxorubicin (red bar) and dye-loading content (DLC) for IR780 (green bar) in all nanoparticles. (b) Intracellular enzymatic biodegradation (schematic). (c) *In vitro* DOX-release kinetics (in hours) of SB-60 + DOX nanoparticle in PBS alone and in the presence of esterase (10 U) and α -Chymotrypsin (8 U) at pH 7.4 incubated at 37 °C (concentration of SB-60 + DOX nanoparticle = 1 mg mL⁻¹). (d) CLSM images of a live cell experiment carried out with SB-60 + DOX unimolecular micelle in WT-MEF cells (DOX concentration = 5 $\mu\text{g mL}^{-1}$, incubation time = 5, 15, 60, 90 and 180 min) and employing LysoTracker™ Red DND-99 to stain lysosomes. DOX was excited using a 488 nm laser and LysoTracker excitation was done using a 561 nm laser (scale bar = 10 μm). (e) Toxicity of free DOX and SB-60 + DOX in the WT-MEF cell line at concentrations up to 1 $\mu\text{g mL}^{-1}$ of DOX. (f) Plot of % Hemolysis vs. polymer concentration for the star block copolymer SB-60. Triton-X served as the positive control.

units. The collapsing of a polymer chain in each-arm is typically a chain length-dependent process, and it seems 60 carboxylic units was the optimum length in the present star-polymer design. We wished to rationalize the role of topology of the star-block copolymer architectures towards its ability to self-assemble into unimolecular micelles in aqueous medium. Hence, two controlled molecules having linear di-block (LB-60) and star-random copolymer (SR-60, no segregation of core and shell) architectures were made. The chemical compositions and molecular weights of SB-60, LB-60 and SR-60 were identical, and they differed only by the arrangements of repeating units (Fig. S6a†). SR-60 self-assembled as a NP of size $D_h = 30 \pm 5$ nm, like that of SB-60 (Fig. S6b†). However, the linear di-block LB-60 exhibited a D_h of 170 ± 10 nm with respect to the formation of large-sized aggregated micelles (FESEM and HR-TEM images in Fig. S6c†). The pyrene-encapsulation experiment for LB-60 showed a breakpoint with respect to a critical micellar concentration of 1 $\mu\text{g mL}^{-1}$ (Fig. S6c†), as typically reported for aggregated micelles. SR-60 and LB-60 exhibited DLC = 3% and 2% for DOX encapsulation which was almost 7-fold lower than that of SB-60 star-UMM (Fig. 3a). Furthermore, the linear di-block copolymer LB-10 was synthesized with 10-PCL units and 10-carboxyl PCL units to mimic the 1-arm of the SB-60 star di-block copolymer

(Fig. S7†) and it demonstrated inferior DOX encapsulation (0.2%). These findings reiterated the importance of polymer topology for producing UMM with a high degree of drug loading and, hence, offers an excellent nanocarrier for drug delivery. All the details of % DLC and drug-loading efficiency (% DLE) for star and linear NPs are summarized in tabular form in Fig. S8.†

An aliphatic polyester backbone in star-UMM makes them fully lysosomal enzymatic-biodegradable, as shown pictorially (Fig. 3b). In the presence of horse-liver esterase enzyme (10 U), >95% drug release was observed within 24 h (Fig. 3c). Enzymatic cleavage by α -Chymotrypsin (8 U) resulted in release of only 60% of DOX molecules. In the control, percentage release was substantially lower (~15%), indicating that the degradation of the UMM occurred only in the presence of lysosomal enzymes. The horse-liver esterase enzyme seemed to be the most suitable for complete degradation of the nano-assemblies (Fig. 3b gives a pictorial representation of the intracellular enzymatic biodegradation). The time-scan CLSM images in Fig. 3d captured cells incubated with SB-60 + DOX unimolecular micelle for the 5–180 min time points (live cell). LysoTracker™ staining helped to visualize the uptake of NPs by the cells and co-localization of the DOX signal at lysosomal compartments. The signals from LysoTracker (green) and DOX



(red) can be seen as yellow in the merged image. This trend was because the star-nanocarrier was taken up readily by the cells *via* endocytosis and internalized at the lysosomal compartment for biodegradation. A control experiment with free DOX (60 and 90 min time points in Fig. S9†) exhibited no colocalization with LysoTracker, indicating that DOX, being a small molecule, was taken up by the cells *via* diffusion. To determine the cyto-compatibility of these nanocarriers, the MTT assay was employed in WT-MEF cell lines. Various concentrations of the nascent star block copolymer scaffold SB-60 were incubated with WT-MEF cells for 72 h (Fig. S9†). As evident from the histogram, the polymer scaffold displayed 100% biocompatibility up to $100 \mu\text{g mL}^{-1}$, and about 70–80% of cells were viable up to $200\text{--}500 \mu\text{g mL}^{-1}$. Furthermore, the cytotoxicity of the DOX-loaded scaffold SB-60 + DOX showed that the free DOX was more toxic to cells compared with their delivery from the polymer platform (Fig. 3e). The IC_{50} values for free DOX and SB60 + DOX in the WT-MEF cell line was 0.09 ± 0.014 and $0.11 \pm 0.02 \mu\text{g mL}^{-1}$, respectively. Furthermore, the compatibility and efficacy were evaluated for SB-60 and SB-60 + DOX NPs in a neuroblastoma (SH-SY5Y) cell line and data are shown in Fig. S10.† The SB-60 NPs exhibited excellent compatibility, with 100% cell viability up to $100 \mu\text{g mL}^{-1}$. On the other hand SB-60 + DOX ($\text{IC}_{50} = 1.39 \pm 0.11 \mu\text{g mL}^{-1}$) showed slightly better killing compared with nascent DOX ($\text{IC}_{50} = 1.69 \pm 0.12 \mu\text{g mL}^{-1}$), as shown in Fig. S10.† Cellular-uptake studies of SB-60 + DOX in SH-SY5Y cells revealed enhanced fluorescence signals with an increase in incubation time, suggesting an effective delivery ability of the star platform in neuroblastoma, as shown in Fig. S10.† Further hemolysis assays clearly exhibited polymer biocompatibility with negligible hemolysis values at concentrations as high as $1000 \mu\text{g mL}^{-1}$ (Fig. 3f).

The biodistribution and biochemical analysis of the DOX-loaded star-UMM was investigated. Ten female mice (8–12 weeks, balb/c strain, ~25 g) were split into two experimental groups: ‘free DOX’ (group 1) and DOX-loaded star-block copolymer ‘SB-60 + DOX’ (group 2). Each group comprised three mice that were used for confocal imaging analysis of drug uptake by organs and for histology. To understand the biocompatibility of the polymers alone, an additional group ($n = 3$) was constituted as the control group (SB-60; group 3), to confirm that the nascent polymer itself did not alter the physiology of the animal. Histology images of various organs upon SB-60 + DOX uptake *via* H&E staining are shown in Fig. 4a. The high-magnification images ($\times 40$) obtained using a bright field microscope (Carl Zeiss) showed no signs of necrosis, blood clotting, or morphological alterations in any of the tissue samples for mice in the SB-60 + DOX group. However, in the panel corresponding to the free DOX group, some blood clotting was observed in heart tissue and, according to the literature,⁶⁰ this is a sign of cardiotoxicity augmented by free DOX (Fig. S11†). Hence, the star block copolymer DOX-loaded assemblies did not result in any damage to tissues, unlike free DOX. To study the immune response in mice, plasma samples collected from all 10 mice (three groups plus one mouse

injected with $1 \times \text{PBS}$ as control) at 24 h were employed to determine the concentration of five cytokines (IL-2, IL-4, IL-17A, IFN- γ and TNF- α) using cytokine standards. The mouse injected with PBS acted as the negative control, wherein no immune response was expected because PBS is non-immunogenic. Across all groups, cytokine levels were very similar to that observed using PBS, and values were $<5 \text{ pg mL}^{-1}$ (Fig. 4b), thereby suggesting that the nano-formulations were not immunogenic. As can be seen from Fig. 4a, for each mouse, the organs collected 24 h-post-injection were brain, heart, kidneys, liver, and spleen. The DAPI-stained $50 \mu\text{m}$ sections were imaged to measure DOX uptake in brain and heart tissues across different groups, as shown in Fig. 4c ($63\times$ magnification) and Fig. S12† ($63\times$ magnification). Images from the kidney, liver, spleen, brain, and heart ($10\times$ magnification) are shown in Fig. S12.† In Fig. 4c, in the brain images, only the SB-60 + DOX nano-formulation exhibited a strong red fluorescence signal (DOX) whereas, a substantially low signal was observed in the free DOX group. This finding was attributed to the SB-60 + DOX UMM being $18\text{--}30 \text{ nm}$, making them ideal nano-formulations to cross the BBB. These SB-60 + DOX micelles passively and selectively cross the BBB, accumulate in brain tissue and, being stable at infinite dilution, would not result in premature release of the drug. Another positive aspect for these SB-60 + DOX micelles was their ability to reduce uptake in heart tissue, as can be seen from Fig. 4c. The signal of the SB-60 + DOX micelles was extremely weak compared with the strong red signal corresponding to free DOX. This was one of the highlights of our study because the major side effect of chemotherapy with DOX is cardiotoxicity. Hence, reducing uptake of DOX in the heart by means of the nano-formulations would greatly overcome the toxic effects of DOX. Thus, the current design of SB-60 UMM can overcome the limitation, and facilitates the use of even higher doses of DOX for chemotherapy in the long-term. The DOX uptake from confocal images was quantified by determining the normalized mean gray values, and shown in the form of bar plots in Fig. 4c. These values for the SB-60 + DOX micelle exhibited enhanced uptake in the brain and drastically reduced uptake by the heart compared with an opposing trend in the free DOX group. Renal clearance was higher in case of free DOX compared with that in the other group. SB-60 + DOX exhibited reduced RES uptake, as can be seen from the low mean gray values in the liver and spleen tissues. An important observation was the significantly higher uptake of SB-60 + DOX UMM in brain tissue compared with free DOX. This was further closely investigated by measuring DOX biodistribution across brain regions under different conditions.

Five areas of the brain (cerebellum, amygdala, hippocampus, cortex, and olfactory bulb (OB)) were chosen for further analysis (posterior to anterior; see the labelling on the sagittal section of the mouse brain in Fig. 5a, adapted from the Gene Expression Nervous System Atlas).⁶¹ Quantifying the DOX intensities from the confocal images in Fig. 5b led to interrogation of whether the nano-formulations were taken up equally by different parts of the brain. The representative con-






Fig. 4 *In vivo* biodistribution of DOX-loaded star nanovector. (a) Mice underwent transcatheter perfusion and the specified organs were dissected for carrying out biodistribution analyses. Hematoxylin and eosin (H&E)-stained tissue samples for SB-60 + DOX imaged at 40 \times magnification (scale bar = 20 μ m). (b) Concentration of the cytokines IL-2, IL-4, IL-17A, IFN- γ and TNF- α in plasma samples of 10 mice. (c) Immunofluorescence images depicting the uptake of free DOX and SB-60 + DOX for brain and heart tissues imaged at 63 \times (scale bar = 50 μ m). Plot of normalized mean gray values representing the quantification of uptake of free DOX and SB-60 + DOX in brain, heart, kidney, liver and spleen tissue samples. Each point represents the mean \pm SEM ($n = 12$) (**** $P < 0.0001$, *** $P = 0.001$).

focal images (Fig. 5b) exhibited that the DOX intensities visibly decreased upon going from the posterior part (cerebellum) to the most anterior part (OB). This was corroborated by the quantification of DOX intensities as normalized mean gray values plotted against the corresponding region of the brain (Fig. 5b). This trend could be attributed to the variation in BBB heterogeneity and permeability across different brain regions, which depends on differential astrocyte and pericyte coverage, differences in tight-junction proteins such as zonula occludens (ZO)-1 and ZO-2, variation in cellular interactions between white matter and gray matter in different regions, and changes in vascular density.⁶² To validate the ability of star block copolymer UMM to enter neurons upon crossing the BBB, an *in vitro* time-dependent experiment was envisaged. Herein, SB-60 + DOX UMM were incubated with the OB and a mixed

cortical primary neuronal culture for 1 h and 4 h followed by immunocytochemistry, and the panels are shown in Fig. 5c. Staining (DAPI and MAP2 antibody) was employed for imaging the differentiated mature neurons, represented *via* the blue ($\lambda_{\text{exc}} = 405$ nm) and green channels ($\lambda_{\text{exc}} = 633$ nm), respectively. DOX emission (red channel, $\lambda_{\text{exc}} = 488$ nm) from the UMMs had substantial co-localization with neuronal markers. The SB-60 + DOX uptake in OB and cortical neurons was quantified. The plot of uptake (%) vs. time revealed significantly higher uptake of SB-60 + DOX UMM in cortical neurons as compared with that in OB neurons across both time points (Fig. 5c). The *in vitro* neuronal culture data were in alignment with the *in vivo* brain biodistribution data, wherein UMM uptake was higher in the cortex as opposed to the OB (Fig. 5b). To examine the cell specificity of these micelles in brain






Fig. 5 Brain-specific delivery and mechanism for BBB crossing. (a) Different areas of mouse brain utilized for quantification of SB-60 + DOX uptake on a sagittal section (Lamp5 gene expression in a transgenic Cre mouse), adapted from the Gene Expression Nervous System Atlas. (b) CLSM images (10 \times) depicting the uptake of unimolecular micelle SB-60 + DOX across different parts of the brain, and plot of normalized mean gray value compared across different regions of brain tissue for the SB-60 + DOX nanoparticle. Each point represents the mean \pm SEM ($n = 10$) (** $P = 0.0019$, * $P = 0.0208$). (c) *In vitro* primary neuronal culture time-dependent experiment representing uptake of SB-60 + DOX in the olfactory bulb and mixed cortical neurons. Plot of uptake (%) vs. time across both neuronal cultures. Each point represents the mean \pm SEM (** $P < 0.0001$, ** $P = 0.0058$). (d) Immunofluorescence images (63 \times) of MAP2-, NeuN- and GFAP-stained neurons and glial cells in the brain for SB-60 + DOX nanoparticles. Scale bar = 10 μ m.

tissue, immunostaining was carried out marking different brain tissue cell types (*i.e.*, MAP2 for staining mature neurons, NeuN as the nuclei marker and GFAP for labelling glial cells and astrocytes). The intent was to investigate the specificity of DOX-loaded unimolecular micelles across brain tissue (if any), and the results can be seen in Fig. 5d. The emission of DOX coming from within mature neurons appeared to co-localize with markers, as can be seen from the merged images (10 \times -first column and 63 \times -second column) in Fig. 5d. This affirmed intracellular uptake of the cargo and that uptake was similar across the brain tissue with no specificity for any cell type.

NIR dye IR780, having excitation in the NIR region, overcomes the limitation of tissue auto-fluorescence while offering the advantage of deeper penetration into tissue.^{63,64} Two groups of mice ($n = 3$) were used. Mice injected with free IR780 iodide dye (group 1) and SB-60 + IR780 (group 2) were utilized along with a control mouse (injected with 1 \times PBS) for *in vivo* biodistribution using the *In Vivo* Imaging System (IVIS) from PerkinElmer. The IVIS imaging for tracking the biodistribution was carried out at 24 h, 48 h and 72 h, as can be seen in Fig. 6a (dorsal view). Using the dorsal view images of mice, an attempt was made to quantify the IR780 distribution in the most rostral part of the body with time across the two groups

by selecting a region of interest (ROI). The plot of total radiant efficiency vs. time in Fig. 6a clearly demonstrated that UMM SB-60 + IR780 exhibited a superior potential to penetrate the BBB as opposed to the free dye, and that this distribution did not change with time up to 72 h. Plasma samples were also subjected to IVIS imaging to quantify the amount of IR780, and the representative photographic image of the wells can be seen in Fig. 6b. The SB60 + IR780 nano-scaffolds demonstrated their ascendancy in their ability to be in circulation for longer than the free dye (see plot of total flux vs. time). The whole-organ representative IVIS image for the major organs captured at the 72 h time point can be seen in Fig. 6c. As can be seen from the average radiant efficiency plot, the SB-60 + IR780 unimolecular micelle had higher uptake in all the tissues compared with free IR780 dye. The whole-organ imaging reiterated the ability of the SB-60 + IR780 star UMM to breach the BBB.

A mechanism illustrating the ability of the nano-scaffold to penetrate the BBB compared with that of the free drug is outlined in Fig. 7a. Transcytosis across the barrier is dictated by factors such as lipophilicity, size, charge, molecular weight and, even with the requisite parameters, molecules undergo efflux out into the blood stream *via* the P-glycoprotein (Pgp) pump.^{65–67} The crucial parameters for NPs intended to pene-






Fig. 6 Time-dependent IVIS-based biodistribution Analysis. (a) Diagrammatic illustration of IR-780-encapsulated SB-60 nanoparticles and time-dependent IVIS-mediated biodistribution analysis of free IR-780 and SB-60 + IR780 UMM along with a control mouse injected with 1x PBS (dorsal view). Plot of total radiant efficiency vs. time quantifying the amount of dye IR780 in the most rostral body region. Each point represents the mean \pm SEM ($n = 3$) (** $P = 0.0005$, * $P = 0.0133$, ** $P = 0.0084$). (b) Representative image of plasma samples captured in a 96-well plate via IVIS. Plot of total flux vs. time depicting the amount of IR780 dye in plasma samples collected at different time points. Each point represents the mean \pm SEM ($n = 3$) (** $P = 0.0096$, ** $P = 0.0063$, ** $P = 0.005$). (c) IVIS-based whole-organ imaging of brain, heart, kidneys, liver and spleen. Whole-organ image-based quantification represented as the plot of average radiant efficiency depicting the amount of dye IR780 in various tissues measured 72 h after injection, for free dye and SB-60 + IR780. Each point represents the mean \pm SEM ($n = 3$) (* $P = 0.0315$, * $P = 0.0287$, * $P = 0.0190$, * $P = 0.0182$ and * $P = 0.0445$ for brain, heart, kidney, liver and spleen, respectively).

trate the BBB are size <50 nm, appropriate lipophilicity, and the surface charge should be near neutral.^{65–67} In the current investigation, a plausible mechanism of BBB breach can be ascribed to caveolae-mediated transcytosis, which transports albumin-like macromolecules from the luminal side to brain parenchyma.^{65–67} Crossing of the BBB by the star block copolymer UMM in the present study could be attributed to three main factors: (i) prolonged circulation in blood making it more bioavailable; (ii) appropriate lipophilicity favorable for transcytosis; (iii) the presence of carboxylate groups on the periphery that circumvent Pgp efflux pumps. These factors, combined with the size range of the UMM (<30 nm), could aid in breaching the BBB. Having established the ability of star UMM to cross the BBB, another crucial investigation was to determine whether the integrity of the BBB was compromised in this process. The Evans Blue (EB) extravasation assay^{68,69} and IR780 breaching ability across the BBB were employed as tools. EB, being a BBB-impermeable dye, was chosen to evaluate BBB disruption by detecting its presence in brain tissue. As can be seen in Fig. 7b and Fig. S13,[†] blue coloration was not observed in the brain tissues of control- and SB60-treated groups, suggesting that the integrity of BBB was maintained upon administration of star-UMM polymer

(SB60). Furthermore, the amounts of dye leaked into brain tissue were quantified, and it was found to be similar in the SB60 group and control group. In another experiment, mice were initially treated with SB60 nascent NPs for 24 h followed by administration of free IR780 for 24 h, as can be seen in Fig. 7c. In the scenario that the BBB integrity was disrupted by the star UMM, there would be significant uptake of IR780 dye. The IVIS image of brain tissues in Fig. 7c clearly demonstrates that IR780 was taken up significantly when delivered via the star-UMM platform. On the other hand, treatment with nascent SB60 (without IR780) for 24 h followed by treatment with free IR780 did not show significant uptake. These investigations suggested that the star-UMM displayed the unique ability to cross the BBB without compromising its integrity. Taking cognizance of *in vivo* and *in vitro* analyses, star-UMM demonstrated an excellent capability to breach the most tightly regulated biological barrier: the BBB. These findings call for further experiments employing potential delivery systems combined with targeted delivery⁷⁰ and precise behavioral paradigms controlling sensory experiences.^{71–75} Our results provide a potential drug-delivery method for brain tumors, and add significantly to the emerging field of “cancer neuroscience” research.






Fig. 7 Mechanistic studies for penetration and integrity of the BBB. (a) Plausible mechanism illustrating the ability of the SB-60 UMM to breach the BBB compared with the free drug. (b) Pictures of brain tissue harvested from mice injected with PBS and SB60, followed by EB, and the dye leakage quantified for both groups. (c) Schematic of the assay devised to elucidate the BBB integrity upon treatment with SB-60. Plot depicting the uptake of IR780 dye to brain tissue in the case of SB60 + IR780, free IR780 and control group where IR780 was injected 24 h after the SB60 injection along with images captured using IVIS.

Conclusions

Tracing through the plethora of star and linear polymer architectures, the unique star block UMM evinced the crucial factors necessary for a BBB nanocarrier. The factors were the star macromolecular topology, size <50 nm, UMM assembly, as well as the ability to carry and deliver a high amount of desired payload across the BBB. The data for *in vitro* cellular uptake suggested an internalization mechanism of DOX-loaded UMM *via* endocytosis and their enzymatic-biodegradation at lysosomal compartments. A myriad of experiments were carefully designed to explore the potential of the star UMM *in vivo*. The pharmacokinetics evaluation established the high bioavailability of star UMM nanocarriers owing to their stability against dilution. The biodistribution of the star-UMM was visualized in real-time by employing IVIS, which reiterated the potential of the UMM to penetrate the BBB to deliver dyes/drugs. The star polymer nano-formulations were non-immunogenic and biocompatible. UMM uptake in brain tissue was influenced by BBB heterogeneity; *in vitro* data for primary neuronal cultures also demonstrated enhanced uptake of the UMM by mixed cortical neurons. Hence, the current star-polymer design opens up oppor-

tunities for UMMs and demonstrates their ability to penetrate the BBB *in vivo* to deliver drugs which could be useful for the treatment of brain-related malignancies.

Notes

The authors declare no competing financial interest.

All animal procedures were carried out at National Facility for Gene Function in Health and Diseases (Indian Institute of Science Education and Research (IISER), Pune, India) with compliance of Institutional Animal Ethics Committee (IAEC) at IISER Pune and the Committee for the Control and Supervision of Experiments on Animals (CCSEA), Government of India guidelines. Animal ethics committee approval number is IISER/IAEC/2018-02/07.

Statistics

All analyses were done using Prism 8.0 (GraphPad). One-way ANOVA, Tukey's test, and unpaired *t*-test were performed, and values are represented as the mean ± SEM.



Author contributions

Mehak Malhotra contributed to polymer synthesis, characterization, nano-formulation, *in vitro* and *in vivo* analysis. Meenakshi Pardasani contributed to *in vivo* and brain-tissue analysis. Shahidkhan Pathan contributed to polymer synthesis and *in vivo* brain studies, Priya Srikanth conducted analysis of uptake by brain cells. Karishma Shaw conducted the study using the neuroblastoma cell line. Nixon Abraham and Manickam Jayakannan conceptualized the study, drafted and edited the final version of the manuscript.

Data availability

The authors declare that the data supporting the findings of this study are available within this document and its ESI† files.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

The authors obtained research grants from Science and Engineering Research Board (CRG/2023/000894; New Delhi, India), DBT/Wellcome Trust India Alliance intermediate (IA/I/14/1/501306 to N.A.), DST-Cognitive Science Research Initiative (DST/CSRI/2017/271 to N.A.), and DBT/Wellcome Trust India Alliance senior grant (IA/S/22/2/506517 to N.A.). We thank IISER Pune Microscopy Facility for cellular imaging and PerkinElmer Centre for Excellence IISER Pune. Part of the work was carried at the National Facility for Gene Function in Health and Disease at IISER Pune, supported by a grant from the Department of Biotechnology, Government of India (BT/INF/22/SP17358/2016).

References

- W. A. Banks, *Nat. Rev. Drug Discovery*, 2016, **15**, 275–292.
- I. U. Ali and X. Chen, *ACS Nano*, 2015, **9**, 9470–9474.
- J. Kreuter, *Adv. Drug Delivery Rev.*, 2001, **47**, 65–71.
- L. Gastaldi, L. Battaglia, E. Peira, D. Chirio, E. Muntoni, I. Solazzi, M. Gallarate and F. Dosio, *Eur. J. Pharm. Biopharm.*, 2014, **87**, 433–444.
- W. Tang, W. Fan, J. Lau, L. Deng, Z. Shen and X. Chen, *Chem. Soc. Rev.*, 2019, **48**, 2967–3014.
- Y. Chen and L. Lu, *Adv. Drug Delivery Rev.*, 2012, **64**, 640–665.
- Y. Zhaou, Z. Peng, E. S. Seven and R. M. Leblanc, *J. Controlled Release*, 2018, **270**, 290–303.
- J. Kreuter, *Adv. Drug Delivery Rev.*, 2014, **71**, 2–14.
- S. Wohlfart, S. Gelperina and J. Kreuter, *J. Controlled Release*, 2012, **161**, 264–273.
- Y. Liu, Y. Zou, C. Feng, A. Lee, J. Yin, R. Chung, J. B. Park, H. Rizos, W. Tao, M. Zheng, O. C. Farokhzad and B. Shi, *Nano Lett.*, 2020, **20**, 1637–1646.
- W. Lv, J. Xu, X. Li, Q. Xu and H. Xin, *ACS Nano*, 2018, **12**, 5417–5426.
- A. Singh, W. Kim, K. Jeong, C. H. Kang, Y. S. Kim, J. Koh, S. D. Mahajan, P. N. Prasad and S. Kim, *Adv. Healthcare Mater.*, 2016, **26**, 7057.
- G. Morad, C. V. Carman, E. J. Hagedorn, J. R. Perlin, L. I. Zon, N. Mustafaoglu, T.-E. Park, D. E. Ingber, C. C. Daisy and M. A. Moses, *ACS Nano*, 2019, **13**, 13853–13865.
- S. Singh, N. Drude, L. Blank, P. B. Desai, H. Konigs, S. Rutten, K. Langen, M. Moller, F. M. Mattaghy and A. Morgenroth, *Adv. Healthcare Mater.*, 2021, **10**, 2100812.
- R. Prades, B. Oller-Salvia, S. M. Schwarzmaier, J. Selva, M. Moros, M. Balbi, V. Grazu, J. M. de La Fuente, G. Egea, N. Plesnila, M. Teixido and E. Giralt, *Angew. Chem., Int. Ed.*, 2015, **54**, 3967–3972.
- D. Gaurneri, A. Falanga, O. Muscetti, R. Torallo, S. Fusco, M. Galdiero, S. Galdiero and P. A. Netti, *Small*, 2013, **9**, 853–862.
- T. Lin, P. Zhao, Y. Jiange, Y. Tang, H. Jin, Z. Pan, H. He, V. C. Yang and Y. Huang, *ACS Nano*, 2016, **10**, 9999–10012.
- C. Martinelli, C. Pucci, M. Battaglini, A. Marino and G. Ciofani, *Adv. Healthcare Mater.*, 2020, **9**, 1901589.
- B. Surnar, A. S. Shah, M. Park, A. A. Kalathil, M. Z. Kamran, R. J. Jaime, M. Toborel, M. Nair, N. Kolishetti and S. Dhar, *ACS Nano*, 2021, **15**, 15741–15753.
- V. Leiro, S. D. Santos, C. D. F. Lopes and A. P. Pego, *Adv. Funct. Mater.*, 2018, **28**, 1700313.
- G. K. Babanyinah, A. Bhadrar, H. Polara, H. Wang, T. Shah, M. C. Biewer and M. C. Stefan, *Chem. Sci.*, 2024, **15**, 9987–10001.
- M. Ayer, M. Schuster, I. Gruber, C. Blatti, E. Kaba, G. Enzmann, O. Burri, R. Guiet, A. Seitz, B. Engelhardt and H.-A. Kloak, *Adv. Healthcare Mater.*, 2021, **10**, 2001375.
- A. K. Sarkar, G. Kura, P. Seth, N. R. Jana and N. R. Jana, *ACS Appl. Nano Mater.*, 2024, **7**, 3468–3478.
- S. Zha, K.-L. Wong and A. H. All, *Adv. Healthcare Mater.*, 2022, **11**, 2102610.
- Y.-B. Miao, K.-H. Chen, C.-T. Chen, F.-L. Mi, Y.-J. Lin, Y. Chang, C.-S. Chiang, J.-T. Wang, K.-J. Lin and H.-W. Sung, *Adv. Mater.*, 2021, **33**, 2100701.
- Y. Gao, Y. Cheng, J. Chen, D. Lin, C. Liu, L.-K. Zhang, L. Yin, R. Yang and Y.-Q. Guan, *Adv. Healthcare Mater.*, 2022, **11**, 2201655.
- D. Reichel, B. Sagong, J. Teh, Y. Zhang, S. Wagner, H. Wang, L. W. K. Chung, P. Butte, K. L. Black, J. S. Yu and J. Manual Perez, *ACS Nano*, 2020, **14**, 8392–8408.
- H. S. Choi, W. Liu, P. Misra, E. Tanaka, J. P. Zimmer, B. I. Ipe, M. G. Bawendi and J. V. Frangioni, *Nat. Nanotechnol.*, 2007, **25**, 1165.
- M. E. Fox, F. C. Szoka and M. J. Frechet, *Acc. Chem. Res.*, 2009, **42**, 1141–1151.



- 30 L. Zhang, K. Yao, Y. Wang, Y. L. Zhou, Z. Fu, G. Li, J. Ling and Y. Yang, *Nano Lett.*, 2021, **21**, 3007–3015.
- 31 R. Pahuja, K. Seth, A. Shukla, R. K. Shukla, P. Bhatnagar, L. K. Singh Chauhan, P. N. Saxena, J. Arun, B. P. Chaudhari, D. K. Patel, S. P. Singh, R. Shukla, V. K. Khanna, P. Kumar, R. K. Chaturvedi and K. C. Gupta, *ACS Nano*, 2015, **9**, 4850–4871.
- 32 H. Guerrero-Cazares, S. Y. Tzeng, N. P. Young, A. O. Abutaleb, A. Quinones-Hinojosa and J. J. Green, *ACS Nano*, 2014, **8**, 5141–5153.
- 33 A. J. Clark and M. E. Davis, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **6**, 12486–12491.
- 34 D.-P. Yang, M. N. N. Linn Oo, G. R. Deen, Z. Li and X. J. Loh, *Macromol. Rapid. Commun.*, 2017, **38**, 1700410.
- 35 J. M. Ren, T. G. McKenzie, Q. Fu, E. H. H. Wong, J. Xu, Z. An, S. Shanmugam, T. P. Davis, C. Boyer and G. G. Qiao, *Chem. Rev.*, 2016, **116**, 6743–6836.
- 36 W. Wu, W. Wang and J. Li, *Prog. Polym. Sci.*, 2015, **46**, 55–85.
- 37 M. Trollsas and J. L. Hedrick, *J. Am. Chem. Soc.*, 1998, **120**, 4644–4651.
- 38 K. M. Fichter, L. Zhang, K. L. Kiick and T. M. Reineke, *Bioconjugate Chem.*, 2008, **19**, 76–88.
- 39 S. P. Chali, S. Azhadri, A. Galstyan, A. H. Groschel and B. J. Ravoo, *Chem. Commun.*, 2021, **57**, 9446–9449.
- 40 V. Karmegam, S. S. Kuruppu, C. M. Udamulle Gedara, M. C. Biewer and M. C. Stefan, *J. Polym. Sci.*, 2021, **59**, 3040–3052.
- 41 G. Chen, Y. Wang, R. Xie and S. Gong, *Adv. Drug Delivery Rev.*, 2018, **130**, 58–72.
- 42 H. Liu, S. Farrell and K. Uhrich, *J. Controlled Release*, 2000, **68**, 167–174.
- 43 B. Kulkarni, M. Malhotra and M. Jayakannan, *Chem. - Asian J.*, 2022, e202101337.
- 44 R. Ghosh, M. Malhotra, R. R. Madhuri Sathe and M. Jayakannan, *Biomacromolecules*, 2020, **21**, 2896–2912.
- 45 B. Kulkarni, M. Malhotra and M. Jayakannan, *ACS Appl. Polym. Mater.*, 2019, **1**, 3375–3388.
- 46 B. Kulkarni and M. Jayakannan, *ACS Biomater. Sci. Eng.*, 2017, **3**, 2185–2197.
- 47 B. Surnar and M. Jayakannan, *Biomacromolecules*, 2016, **17**, 4075–4085.
- 48 M. Malhotra, B. Surnar and M. Jayakannan, *Macromolecules*, 2016, **49**, 8098–8112.
- 49 B. Surnar and M. Jayakannan, *ACS Biomater. Sci. Eng.*, 2016, **2**, 1926–1941.
- 50 B. Kulkarni, B. Surnar and M. Jayakannan, *Biomacromolecules*, 2016, **17**, 1004–1016.
- 51 B. Surnar, K. Sharma and M. Jayakannan, *Nanoscale*, 2015, **7**, 17964–17979.
- 52 B. Surnar and M. Jayakannan, *Biomacromolecules*, 2013, **14**, 4377–4387.
- 53 U. Pranav, M. Malhotra, S. Pathan and M. Jayakannan, *ACS Biomater. Sci. Eng.*, 2023, **9**, 743–759.
- 54 R. Ghosh and M. Jayakannan, *Biomacromolecules*, 2023, **24**, 739–755.
- 55 S. Pathan and M. Jayakannan, *Adv. Healthcare Mater.*, 2024, **13**, 2304599.
- 56 P. R. Lockman, J. M. Koziara, R. J. Mumper and D. D. Allen, *J. Drug Targeting*, 2004, **12**, 635–641.
- 57 E. A. Nance, G. F. Woodworth, K. A. Sailor, T.-Y. Shih, Q. Xu, G. Swaminathan, D. Xiang, C. Eberhart and J. Hanes, *Sci. Transl. Med.*, 2012, **4**, 149ra119.
- 58 J. H. Miner, *Kidney Int.*, 2008, **74**, 559–561.
- 59 L. J. M. Vagberg, K. A. Cogan and A. P. Gast, *Macromolecules*, 1991, **24**, 1670–1677.
- 60 H. Tang, J. Zhang, J. Tang, Y. Shen, W. Guo, M. Zhou, R. Wang, N. Jiang, Z. Gan and Q. Yu, *Biomacromolecules*, 2018, **19**, 2849–2862.
- 61 S. Gong, C. Zheng, M. L. Doughty, K. Losos, N. Didkovsky, U. B. Schambra, N. J. Nowak, A. Joyner, G. Leblanc, M. E. Hatten and N. Heintz, *Nature*, 2003, **425**, 917.
- 62 M. Suci, A. Hermenean and I. Wilhelm, *Tissue Barriers*, 2016, **4**, e1143544.
- 63 L. Wang and C. Niu, *J. Mater. Chem. B*, 2021, **9**, 4079–4097.
- 64 U. A. Gavhane, D. C. Joshi and M. Jayakannan, *Biomacromolecules*, 2024, **25**, 3756–3774.
- 65 K. K. Pulicherla and M. Kumar Verma, *AAPS PharmSciTech*, 2015, **16**, 223.
- 66 M. Zhou, S. X. Shi, N. Liu, Y. Jiang, M. S. Karim, S. J. Vodovoz, X. Wang, B. Zhang and A. S. Dumont, *J. Clin. Med.*, 2021, **10**, 3795.
- 67 S. Ayloo and C. Gu, *Curr. Opin. Neurobiol.*, 2019, **57**, 32–38.
- 68 M. P. de Souza Goldim, A. D. Giustina and F. Petronilho, *Curr. Protoc. Immunol.*, 2019, **126**, e83.
- 69 J.-H. Gu, *et al.*, *PLoS One*, 2013, **8**, e61641.
- 70 N. M. Abraham, V. Egger, D. R. Shimshek, R. Renden, I. Fukunaga, R. Sprengel, P. H. Seeburg, M. Klugmann, T. W. Margrie, A. T. Schaefer and T. Kuner, *Neuron*, 2010, **65**, 399–411.
- 71 A. S. Bhattacharjee, S. Konakamchi, D. Turaev, R. Vincis, D. Nunes, A. A. Dingankar, H. Spors, A. Carleton, T. Kuner and N. M. Abraham, *Cell Rep.*, 2019, **28**, 2966–2978.
- 72 N. M. Abraham, D. Guerin, K. Bhaukaurally and A. Carleton, *PLoS One*, 2012, **7**, 112.
- 73 S. Mahajan, D. Sen, A. Sunil, P. Srikanth, S. D. Marathe, K. Shaw, M. Sahare, S. Galande and N. M. Abraham, *Front. Neurosci.*, 2023, **17**, 1180868.
- 74 M. Pardasani, S. D. Marathe, M. M. Purnapatre, U. Dalvi and N. M. Abraham, *FASEB J.*, 2021, **9**, 35.
- 75 M. Pardasani, A. M. Ramakrishnan, S. Mahajan, M. Kantroo, E. McGowan, S. Das, P. Srikanth, S. Pandey and N. M. Abraham, *Mol. Psychiatry*, 2023, **28**, 4693–4706.

